Chemical Nature and Mechanism of Action
Cycloserine is a unique antibacterial drug whose mechanism of action relies on molecular mimicry. Chemically, it is a structural analog of D-alanine, an essential amino acid required for the construction of a functional bacterial cell wall.
Upon entering the cell, the drug acts as an irreversible inhibitor. It binds tightly to key bacterial enzymes, completely blocking their function. The two primary targets are:
- Alanine racemase. Under normal conditions, this enzyme catalyzes the spatial reconfiguration of L-alanine into D-alanine. Cycloserine halts this process at the very first step.
- D-alanyl-D-alanine ligase. If any D-alanine is successfully synthesized, this second enzyme joins two D-alanine molecules into a single dipeptide. Cycloserine blocks this reaction as well.
As a result of this dual irreversible inhibition, the bacterial cell is deprived of essential building blocks, cell wall synthesis stops, and the microorganism inevitably dies.
Clinical Indications and Resistance
In modern pharmacology, cycloserine is strictly a second-line drug, or reserve agent. It is not used for routine therapy due to its safety profile.
The primary indication is multidrug-resistant tuberculosis (MDR-TB). When mycobacteria fail to respond to standard first-line drugs, cycloserine becomes a vital component of combination therapy. It is also used for certain urinary tract infections. This is directly linked to its pharmacokinetics: similar to fosfomycin, cycloserine is excreted in the urine, achieving high therapeutic concentrations in the urinary tract.
However, clinical use is severely limited by the fact that resistance develops rapidly. Bacteria utilize two main mechanisms of resistance:
- Target overexpression. Microorganisms begin synthesizing alanine racemase in massive quantities. The enzyme molecules become so numerous that the drug is insufficient to block them all.
- Transport system mutations. Because cycloserine mimics alanine, it enters the cell via the same transport channels responsible for alanine uptake. By mutating these transport systems, the bacterium effectively "closes the door" on the antibiotic.
Safety Profile and Drug Interactions
The use of cycloserine requires high clinical vigilance due to its specific adverse effect profile. The drug exhibits marked neurotoxicity. Patients can develop severe complications, including seizures, acute psychosis, and painful peripheral neuropathy.
To minimize these risks, it is critical to account for drug interactions:
- Enhanced toxicity. Alcohol consumption is strictly contraindicated. Furthermore, neurotoxicity is mutually exacerbated when combined with other antitubercular drugs such as isoniazid and ethionamide.
- Pharmacological protection. To mitigate side effects and protect nerve fibers, pyridoxine (vitamin B6) must be included in the treatment regimen. Its administration reliably reduces the incidence and severity of peripheral neuropathy.
- Effect on other drug metabolism. Cycloserine can interfere with hepatic enzyme systems. Specifically, it inhibits the hepatic metabolism of phenytoin, requiring close monitoring during co-administration.